Business
M3 : Notice Concerning Differences between Actual Non-Consolidated Results for the Fiscal Year Ended March 31, 2025 and the Previous Fiscal Year Ended March 31, 2024
M3 : Notice Concerning Differences between Actual Non-Consolidated Results for the Fiscal Year Ended March 31, 2025 and the Previous Fiscal Year Ended March
About this update from M3, Inc.
[{"type":"text","content":"\n Disclaimer: This document is a translation of the original Japanese version. The original Japanese version was prepared and disclosed by the Company in accordance with Japanese accounting standards. This document does not contain or constitute any guarantee and the Company will not compensate for any losses or damages arising from interpretations or actions taken based on this document. In the case of any discrepancies between the Japanese original and this document, the Japanese original is assumed to be correct.\n \n \n FOR IMMEDIATE RELEASE: 2025/5/2\n \n Listed Name:\n \n \n M3, Inc.\n \n \n (TSE Prime Market, Ticker Code: 2413)\n \n \n (https://corporate.m3.com/en)\n Headquarters：\n Akasaka Intercity, 1-11-44 Akasaka, Minato-ku, Tokyo\n \n \n Representative:\n \n \n Itaru Tanimura, Representative Director\n \n \n Contact:\n \n \n Hirofumi Oba, Corporate Officer\n \n Notice Concerning Differences between Actual Non-Consolidated Results\n \n \n for the Fiscal Year Ended March 31, 2025 and the Previous Fiscal Year Ended March 31, 2024\n \n \n \n This notice serves to provide information regarding the difference between actual non-consolidated results for the fiscal year ended March 31, 2025 and the results for the previous fiscal year ended March 31, 2024.\n \n \n Differences between actual non-consolidated results for the fiscal year ended March 31, 2025 and the fiscal year ended March 31, 2024 (J-GAAP)\n \n Net sales\n \n \n Operating profit\n \n \n Ordinary profit\n \n \n Profit\n \n \n Actual results for the\n \n \n fiscal year ended March 31, 2024 (A)\n \n \n Millions of Yen\n \n \n Millions of Yen\n \n \n Millions of Yen\n \n \n Millions of Yen\n \n \n 51,520\n \n \n 23,596\n \n \n 84,032\n \n \n 75,943\n \n \n Actual results for the fiscal year ended\n \n \n March 31, 2025 (B)\n \n \n \n 45,249\n \n \n \n 19,119\n \n \n \n 27,464\n \n \n \n 21,433\n \n \n Difference (B - A)\n \n \n -6,271\n \n \n -4,477\n \n \n -56,567\n \n \n -54,510\n \n \n Difference (%)\n \n \n -12.2\n \n \n -19.0\n \n \n -67.3\n \n \n -71.8\n \n Reason of differences\n \n \n Regarding the full-year non-consolidated results for the fiscal year ended March 2025, both net sales and operating profit decreased compared to the previous fiscal year. This was primarily due to a year-on-year decline in sales related to pharmaceutical marketing support, r...